Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention
Open Access
- 16 June 2010
- journal article
- review article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 51 (7), 1049-1058
- https://doi.org/10.2967/jnumed.110.075101
Abstract
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs such as octreotide is an effective therapy against neuroendocrine tumors. Other radiolabeled peptides and antibody fragments are under investigation. Most of these compounds are cleared through the kidneys and reabsorbed and partially retained in the proximal tubules, causing dose-limiting nephrotoxicity. An overview of renal handling of radiolabeled peptides and resulting nephrotoxicity is presented, and strategies to reduce nephrotoxicity are discussed. Modification of size, charge, or structure of radiolabeled peptides can alter glomerular filtration and tubular reabsorption. Coinfusion of competitive inhibitors of reabsorption also interferes with the interaction of peptides with renal endocytic receptors; coinfusion of basic amino acids is currently used for kidney protection in clinical PRRT. Furthermore, nephrotoxicity may be reduced by dose fractionation, use of radioprotectors, or use of mitigating agents. Decreasing the risk of nephrotoxicity allows for administration of higher radiation doses, increasing the effectiveness of PRRT.This publication has 60 references indexed in Scilit:
- Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response—Implications for Radionuclide TherapyJournal of Nuclear Medicine, 2008
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differencesNuclear Medicine and Biology, 2007
- Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptideNuclear Medicine and Biology, 2007
- Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analoguesNuclear Medicine and Biology, 2006
- Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearanceNuclear Medicine and Biology, 2006
- Megalin and cubilin, role in proximal tubule function and during developmentPediatric Nephrology, 2002
- Decreased kidney uptake of technetium-99m-labelled Fab′ fragments in ovarian carcinoma bearing nude mice using a cleavable chelatorNuclear Medicine and Biology, 1994